- $52.92m
- -$18.44m
- $27.29m
- 56
- 55
- 21
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.27 | ||
| Price to Tang. Book | 0.54 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.78% | ||
| Return on Equity | -21.57% | ||
| Operating Margin | -187.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 4.13 | 18.93 | 25.19 | 27.29 | 31.8 | 45.33 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's product portfolio includes diagnostics and medical devices that emphasize patient health and practice economics. Its Diagnostics segment consists of TRUFORMA, VETGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi Loop and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field therapy.
Directors
- Jeffrey Rowe NEC (65)
- Larry Heaton CEO (64)
- Ann Cotter CFO (51)
- Stephanie Morley COO (46)
- Robert Cohen DRC (63)
- Sean Whelan DRC (50)
- Christopher MacLeod IND (51)
- Johnny Powers IND (60)
- Rodney Williams IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 7th, 2013
- Public Since
- October 28th, 2013
- No. of Employees
- 152
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 979,949,668
- Address
- 1101 Technology Drive, Suite 100, ANN ARBOR, 48108
- Web
- https://zomedica.com/
- Phone
- +1 7343692555
- Auditors
- Grant Thornton LLP
Upcoming Events for ZOMDF
Zomedica Corp Annual Shareholders Meeting
Q2 2025 Zomedica Corp Earnings Release
Q2 2025 Zomedica Corp Earnings Release
Similar to ZOMDF
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
What is the Zomedica share price?
As of Today at 24:17 UTC, shares in Zomedica are trading at $0.05. This share price information is delayed by 15 minutes.
How has the Zomedica share price performed this year?
Shares in Zomedica last closed at $0.05 and the price had moved by -58.49% over the past 365 days. In terms of relative price strength the Zomedica share price has underperformed the S&P500 Index by -61.22% over the past year.
What are the analyst and broker recommendations for Zomedica?
The overall consensus recommendation for Zomedica is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Zomedica dividend yield?
Zomedica does not currently pay a dividend.
Does Zomedica pay a dividend?
Zomedica does not currently pay a dividend.
When does Zomedica next pay dividends?
Zomedica does not currently pay a dividend.
How do I buy Zomedica shares?
To buy shares in Zomedica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zomedica?
As of the previous close price of $0.05, shares in Zomedica had a market capitalisation of $52.92m.
Where are Zomedica shares listed?
Here are the trading details for Zomedica:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ZOMDF
What kind of share is Zomedica?
Based on an overall assessment of its quality, value and momentum Zomedica is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zomedica share price forecast for 2025?
The analyst consensus target price for shares in Zomedica is $0.25. That is 362.96% above the last closing price of $0.05.
Analysts covering Zomedica currently have a consensus Earnings Per Share (EPS) forecast of -$0.03 for the next financial year.
Find out moreWhat is the trend in the Zomedica share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zomedica. Over the past six months, its share price has underperformed the S&P500 Index by -53.77%.
As of the last closing price of $0.05, shares in Zomedica were trading -53.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zomedica PE Ratio?
The Zomedica PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zomedica?
Zomedica's management team is headed by:
- Jeffrey Rowe - NEC
- Larry Heaton - CEO
- Ann Cotter - CFO
- Stephanie Morley - COO
- Robert Cohen - DRC
- Sean Whelan - DRC
- Christopher MacLeod - IND
- Johnny Powers - IND
- Rodney Williams - IND